Research on the blood concentration of ponatinib and treatment outcome in patients with chronic phase chronic myelogenous leukemia (CP-CML)
Latest Information Update: 02 Feb 2022
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Pharmacokinetics
- Sponsors Otsuka Pharmaceutical
- 01 Feb 2022 According to UMIN, the date for trial data considered completed is 31 Dec 2022, and date of conclusion of data analysis is 31 Mar 2023.
- 01 Feb 2022 Planned End Date changed from 30 Jun 2023 to 30 Sep 2022.
- 01 Feb 2022 Status changed from recruiting to active, no longer recruiting.